HomeGrants › PAR-27-125

Forecasted

Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)

Federal funding opportunity PAR-27-125 from National Institutes of Health.

View forecast on Grants.gov →Forecasted — not yet open

Posted
July 1, 2026
Closes
See announcement
Cost sharing
No
Instrument
Cooperative Agreement
Assistance listing
93.840, 93.837, 93.233, 93.838, 93.839
Category
Health

Program funding history

Awards made under Assistance Listing 93.840 across FY2024–FY2026, from public federal spending records.

FY2024 obligated
$1.2M
FY2025 obligated
$2.1M
FY2026 (to date) obligated
$0
Awards in window
88

Top recipients: The Regents of the University of Colorado, Indiana Department of Health, Minnesota Department of Health, Michigan Public Health Institute, City of Philadelphia

Source: USAspending.gov · refreshed July 2026

Synopsis

The NIH intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications to develop and implement investigator-initiated multi-site clinical trials, including efficacy, effectiveness, pragmatic, and/or implementation research clinical trials. Applications that propose a large and/or complex clinical trial conducted at either a single site or at multiple locations but without physical clinical sites (e.g., decentralized or virtual trials) may also be eligible. Proposed trials must be relevant to the research mission of the participating ICs and meet the NIH definition of a clinical trial (see NOT-OD-15-015 and NOT-OD-26-032). The objective of the application is to present 1) the scientific rationale as well as a comprehensive scientific and operational plan for the trial, and 2) a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the clinical trial. 

Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize a bi-phasic (UG3/UH3), milestone-driven mechanism consisting of a start-up phase up to 2 years (UG3) and a full enrollment and clinical trial implementation phase up to 5 years (UH3), for a total award duration of up to 7 years. A UG3 project that meets its milestones will be administratively considered for transition to the UH3 award. Investigators with expertise and insights into this area are encouraged to begin to consider applying for this NOFO. 

Who can apply

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

How to apply

Applications go through the official government listing. Grants Radar links you straight to the source.

View on Grants.gov

Agency contact: National Heart, Lung, and Blood Institute (NHLBI) · NHLBIDCVSClinical@mail.nih.gov · Please contact via e-mail.

Get grants like this every Tuesday — free

One email a week: the biggest new federal grants and what’s closing soon. Unsubscribe in one click.

The free edition carries one clearly labeled sponsor slot. No spam, ever. Privacy

Similar grants

Never miss a funding deadline again

Grants Radar sends AI-enriched alerts on federal grants and contracts matched to what you do. Founding seats are limited and locked for life.

Get funding alerts